Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…matched healthy controls. A subgroup of 5 patients treated with Anifrolumab and 5 with Belimumab were evaluated longitudinally, with sample…
…thematous (SLE). We report a case of recurrent ALP treated with anifrolumab.Methods A 47-year-old man presented in August 2022 with progres…
… 4.0 (https://creativecommons.org/licenses/by/4.0/).Conclusions Anifrolumab demonstrates consistent efficacy across CLE subtypes, and an ac…
…tologic (lymphopenia), and serologic activity (SLEDAI-2K 6–8 on prednisolone 10 mg/day).Results In August 2024, anifrolumab 300 mg IV monthl…
… was used in 68.8% vs 52.9%, Anifrolumab in 12.5% vs 35.3%, and Rituximab in 18.8% vs 11.8% (early vs late).The most frequent clinical ma…
…H, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117–28. doi: 10…
… patients treated with the type I IFN receptor-blocking therapy anifrolumab, DN2 frequency and ISP scores significantly decreased.Conclusio…
…I blocking antibody, and an FDA-approved IFN receptor blockade (Anifrolumab) attenuated the pathological change in mitochondria triggered b…
…d HCQ 400 mg/day. In August 2025, due to inadequate efficacy of rituximab (3 g), intolerance to MMF, and limitations on IS (due to leukop…
…treatments included glucocorticoids (72.4%), immunosuppressants—methotrexate, azathioprine, or mycophenolate—(46%) and antimalarials (82.7%)…
…11), antimalarials (n= 55), tacrolimus (n= 27), everolimus (1), belimumab (BLM) (19) and anifrolumab (1). After a follow-up of 59.7±46 mo…
…omitant immunosuppressive biologics in LN patients treated with voclosporin. This is notable given the unique and possibly synergistic effe…